# PACIFIC-4 (NCT03833154)

> Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03833154
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Durvalumab; Placebo; (Osimertinib cohort, single-arm, open-label separate cohort)
- Enrollment: 724
- Primary outcome: Progression-Free Survival (PFS) assessed by Blinded Independent Central Review (BICR) according to RECIST 1.1 in subpopulation of patients with Stage I/II NSCLC
- Primary outcome: 4-year Progression-Free Survival (4y-PFS) by ICR according to RECIST 1.1 criteria

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 23
- Podcasts: 6
- Bluesky threads: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=pacific-4-nct03833154

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03833154", "email": "<work email>"}; the inbox owner confirms by the emailed link.